Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined With Induction in Acute Leukemias Who Exhibit In Vitro Kinase Inhibitor Sensitivity
Sponsor: National Cancer Institute (NCI)
Listed as NCT02779283, this PHASE1 trial focuses on Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2018 — Jun 2020 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- OHSU Knight Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .